{
    "clinical_study": {
        "@rank": "92615", 
        "arm_group": {
            "arm_group_label": "A", 
            "arm_group_type": "Other", 
            "description": "All eligible study participants"
        }, 
        "brief_summary": {
            "textblock": "To quantitate in an HIV-infected population the percentage of patients demonstrating the\n      \"booster\" phenomenon (attainment of a positive response to a second tuberculin purified\n      protein derivative skin test when the first skin test was negative); to determine the\n      relationship between the booster phenomenon and CD4-positive lymphocyte cell counts; to\n      detect any relationship between the booster phenomenon and HIV exposure category.\n\n      The accuracy of skin testing to detect Mycobacterium tuberculosis (MTb) infection is\n      dependent upon the host's ability to mount a delayed-type hypersensitivity (DTH) reaction;\n      however, the DTH response may be impaired or absent in patients with impaired cell-mediated\n      immunity, a classic characteristic of HIV infection. Patients in whom immunity is\n      diminished, but not absent, may test negative the first time a purified protein derivative\n      skin test for MTb is administered, but if the same skin test is repeated, a positive DTH\n      response may then be elicited. This occurrence is known as the \"booster\" phenomenon."
        }, 
        "brief_title": "Two-Stage Tuberculin (PPD) Skin Testing in Individuals With Human Immunodeficiency Virus (HIV) Infection", 
        "completion_date": {
            "#text": "December 1992", 
            "@type": "Actual"
        }, 
        "condition": [
            "HIV Infections", 
            "Tuberculosis"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Acquired Immunodeficiency Syndrome", 
                "HIV Infections", 
                "Immunologic Deficiency Syndromes", 
                "Tuberculosis"
            ]
        }, 
        "detailed_description": {
            "textblock": "The accuracy of skin testing to detect Mycobacterium tuberculosis (MTb) infection is\n      dependent upon the host's ability to mount a delayed-type hypersensitivity (DTH) reaction;\n      however, the DTH response may be impaired or absent in patients with impaired cell-mediated\n      immunity, a classic characteristic of HIV infection. Patients in whom immunity is\n      diminished, but not absent, may test negative the first time a purified protein derivative\n      skin test for MTb is administered, but if the same skin test is repeated, a positive DTH\n      response may then be elicited. This occurrence is known as the \"booster\" phenomenon.\n\n      Patients who have had a negative purified protein derivative (PPD) skin test for M.\n      tuberculosis within 7-28 days prior to study entry will receive a second PPD test by the\n      Mantoux method (5 TU intradermally to the volar aspect of the forearm). Skin tests will be\n      read 48-72 hours after application. Patients with a positive skin test (defined as an\n      induration, or small hard knot, of 5 mm or greater forming beneath the skin) will be\n      referred to their primary physicians for further evaluation."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria\n\n        Patients must have:\n\n          -  HIV infection.\n\n          -  Negative PPD skin test within previous 7-28 days.\n\n        Exclusion Criteria\n\n        Concurrent Medication:\n\n        Excluded:\n\n          -  Steroids.\n\n          -  Live viral vaccines.\n\n          -  Antihistamines.\n\n          -  Chemoprophylaxis or chemotherapy for suspected or confirmed tuberculosis.\n\n        Patients with the following prior conditions are excluded:\n\n          -  History of documented positive PPD skin test.\n\n          -  History of tuberculosis or who are presently receiving chemoprophylaxis or\n             chemotherapy for suspected or confirmed tuberculosis.\n\n          -  History of sensitivity to tuberculin or components of PPD.\n\n        Prior Medication:\n\n        Excluded:\n\n          -  Live viral vaccine within the past 4 weeks.\n\n          -  Steroid therapy within the past 4 weeks.\n\n          -  Antihistamines within the past week.\n\n          -  Chemoprophylaxis or chemotherapy for suspected or confirmed tuberculosis."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "13 Years"
        }, 
        "enrollment": {
            "#text": "864", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 2, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00000955", 
            "org_study_id": "CPCRA 008", 
            "secondary_id": "11560"
        }, 
        "intervention": {
            "arm_group_label": "A", 
            "description": "Administered intradermally at 5 TU per 0.1 mL", 
            "intervention_name": "Tuberculin Purified Protein Derivative", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "Tuberculosis", 
            "Immunologic Tests", 
            "Tuberculin", 
            "Tuberculin Test", 
            "AIDS-Related Opportunistic Infections", 
            "Injections, Intradermal", 
            "Acquired Immunodeficiency Syndrome", 
            "AIDS-Related Complex", 
            "Hypersensitivity, Delayed"
        ], 
        "lastchanged_date": "September 28, 2013", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "New Haven", 
                        "country": "United States", 
                        "state": "Connecticut", 
                        "zip": "06519"
                    }, 
                    "name": "Hill Health Corp"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Wilmington", 
                        "country": "United States", 
                        "state": "Delaware", 
                        "zip": "19899"
                    }, 
                    "name": "Wilmington Hosp / Med Ctr of Delaware"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Washington", 
                        "country": "United States", 
                        "state": "District of Columbia", 
                        "zip": "20422"
                    }, 
                    "name": "Veterans Administration Med Ctr / Regional AIDS Program"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chicago", 
                        "country": "United States", 
                        "state": "Illinois", 
                        "zip": "60657"
                    }, 
                    "name": "AIDS Research Alliance - Chicago"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "New Orleans", 
                        "country": "United States", 
                        "state": "Louisiana", 
                        "zip": "70112"
                    }, 
                    "name": "Louisiana Comm AIDS Rsch Prog / Tulane Univ Med"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Detroit", 
                        "country": "United States", 
                        "state": "Michigan", 
                        "zip": "48202"
                    }, 
                    "name": "Henry Ford Hosp"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Detroit", 
                        "country": "United States", 
                        "state": "Michigan", 
                        "zip": "48201"
                    }, 
                    "name": "Comprehensive AIDS Alliance of Detroit"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Newark", 
                        "country": "United States", 
                        "state": "New Jersey", 
                        "zip": "07103"
                    }, 
                    "name": "North Jersey Community Research Initiative"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bronx", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10456"
                    }, 
                    "name": "Bronx Lebanon Hosp Ctr"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Brooklyn", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "11201"
                    }, 
                    "name": "Addiction Research and Treatment Corp"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10011"
                    }, 
                    "name": "Clinical Directors Network of Region II"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10037"
                    }, 
                    "name": "Harlem AIDS Treatment Group / Harlem Hosp Ctr"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Portland", 
                        "country": "United States", 
                        "state": "Oregon", 
                        "zip": "97210"
                    }, 
                    "name": "Portland Veterans Adm Med Ctr / Rsch & Education Grp"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Richmond", 
                        "country": "United States", 
                        "state": "Virginia", 
                        "zip": "23298"
                    }, 
                    "name": "Richmond AIDS Consortium"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Two-Stage Tuberculin (PPD) Skin Testing in Individuals With Human Immunodeficiency Virus (HIV) Infection", 
        "overall_official": [
            {
                "last_name": "Thompson C", 
                "role": "Study Chair"
            }, 
            {
                "last_name": "Gordin F", 
                "role": "Study Chair"
            }
        ], 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Federal Government"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 1992", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "To estimate the percentage of HIV-infected individuals who demonstrate the booster effect", 
            "safety_issue": "No", 
            "time_frame": "Throughout study"
        }, 
        "reference": [
            {
                "citation": "Thompson C, Gordin F, Muth K, Daniels K, Matts J, Maiatico G, Deyton L. Two stage tuberculin (PPD) skin testing in individuals with HIV infection. Int Conf AIDS. 1992 Jul 19-24;8(3):140 (abstract no PuB 7546)"
            }, 
            {
                "PMID": "7881675", 
                "citation": "Webster CT, Gordin FM, Matts JP, Korvick JA, Miller C, Muth K, Brown LS, Besch CL, Kumi JO, Salveson C, et al. Two-stage tuberculin skin testing in individuals with human immunodeficiency virus infection. Community Programs for Clinical Research on AIDS. Am J Respir Crit Care Med. 1995 Mar;151(3 Pt 1):805-8."
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00000955"
        }, 
        "responsible_party": {
            "name_title": "Rona Siskind", 
            "organization": "DAIDS"
        }, 
        "secondary_outcome": [
            {
                "measure": "To determine the relationships among the booster effect, CD4+ cell count, and other HIV-related patient characteristics", 
                "safety_issue": "No", 
                "time_frame": "Throughout study"
            }, 
            {
                "measure": "To determine the relationship of boosting to CD4+ cell counts, HIV exposure categories, demographics, and TB risk categories", 
                "safety_issue": "No", 
                "time_frame": "Throughout study"
            }, 
            {
                "measure": "To determine the relationship of induration size after the first PPD skin test to that after the second PPD skin test", 
                "safety_issue": "No", 
                "time_frame": "After the second PPD skin test"
            }
        ], 
        "source": "National Institute of Allergy and Infectious Diseases (NIAID)", 
        "sponsors": {
            "collaborator": {
                "agency": "Warner Lambert - Parke Davis", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "National Institute of Allergy and Infectious Diseases (NIAID)", 
                "agency_class": "NIH"
            }
        }, 
        "study_design": "Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening", 
        "study_type": "Interventional", 
        "verification_date": "September 2013"
    }, 
    "geocoordinates": {
        "AIDS Research Alliance - Chicago": "41.878 -87.63", 
        "Addiction Research and Treatment Corp": "40.653 -73.959", 
        "Bronx Lebanon Hosp Ctr": "40.85 -73.867", 
        "Clinical Directors Network of Region II": "40.714 -74.006", 
        "Comprehensive AIDS Alliance of Detroit": "42.331 -83.046", 
        "Harlem AIDS Treatment Group / Harlem Hosp Ctr": "40.714 -74.006", 
        "Henry Ford Hosp": "42.331 -83.046", 
        "Hill Health Corp": "41.308 -72.928", 
        "Louisiana Comm AIDS Rsch Prog / Tulane Univ Med": "29.951 -90.072", 
        "North Jersey Community Research Initiative": "40.736 -74.172", 
        "Portland Veterans Adm Med Ctr / Rsch & Education Grp": "45.523 -122.676", 
        "Richmond AIDS Consortium": "37.541 -77.436", 
        "Veterans Administration Med Ctr / Regional AIDS Program": "38.895 -77.036", 
        "Wilmington Hosp / Med Ctr of Delaware": "39.746 -75.547"
    }
}